ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Herpes zoster is a common condition especially in our aging cohort. There is limited information about the use of HZ vaccine in this group. Paper 96 presented results from a randomised, double-blind, placebo-controlled trial assessing safety and immunogenicity of 2 doses of ZV in HIV+ adults ≥18 years old (CD4 >200 copies/µL; HIV RNA Preliminary data suggest that the vaccine is generally safe, and immunogenic. Further data from this study is awaited.